10x Genomics Hits New 52-Week High on Analyst Upgrade

Shares of the biotech company reach a new high after Citigroup raises its price target.

Apr. 8, 2026 at 2:57pm

Got story updates? Submit your updates here. ›

Shares of 10x Genomics (NASDAQ:TXG) reached a new 52-week high on Wednesday after Citigroup analysts raised their price target on the stock from $18.00 to $24.00 and maintained a neutral rating. The stock traded as high as $23.65 before closing at $23.04, with over 315,000 shares traded.

Why it matters

The 52-week high for 10x Genomics reflects growing investor confidence in the company's advanced genomic analysis solutions, which enable researchers to explore biology at unprecedented resolution. The stock's performance also highlights the biotech sector's continued strength, despite broader market volatility.

The details

Citigroup's price target increase comes after several other research firms have also issued positive updates on 10x Genomics in recent months. The company's flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling, and genome assembly, while its Visium and Xenium platforms offer spatial transcriptomics and in situ analysis capabilities.

  • 10x Genomics stock reached a new 52-week high on Wednesday, April 8, 2026.
  • Citigroup raised its price target on the stock from $18.00 to $24.00 on the same day.

The players

10x Genomics

A biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution.

Citigroup

A global investment bank and financial services corporation that provides research coverage on 10x Genomics.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

The new 52-week high for 10x Genomics reflects the company's strong position in the advanced genomics market and the continued investor appetite for innovative biotech stocks, even amid broader market volatility.